Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Therma Bright Inc V.THRM

Alternate Symbol(s):  TBRIF

Therma Bright Inc. is a Canada-based company, which is a developer and partner in a range of diagnostic and medical device technologies. It focuses on providing consumers and medical professionals with solutions that address medical and healthcare challenges. It is involved in developing, acquiring, manufacturing, and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace. Its product offerings include Covid-19 diagnostic test product line, such as AcuVid COVID-19 Rapid Antigen Saliva Test and AcuVid COVID-19 Rapid Antibody Test; Sores & Bite Inflammation Therapy product line, such as InterceptCS Cold Sore Prevention System and TherOZap, and Muscle Pain & Blood Circulation Health Therapy product line, such as Venowave, which is a circulation booster designed to improve circulation in the lower extremities. Its products include Benepod, Inretio, AI4LYF, Invixa and Instatin, and others.


TSXV:THRM - Post by User

Comment by birch1on Sep 12, 2022 6:15pm
109 Views
Post# 34957995

RE:RE:RE:RE:Now

RE:RE:RE:RE:NowBoudi,
I'm now with you.  I want FDA correspondence to Therma Bright to be open to shareholders to know exactly what they have asked for.  No different from minining company disclosure and applications.  As shareholders, FDA requests are material and should be shared with all investors in this case so we all have insight into the challenges at hand.  FDA requests are material and should be disclosed to the public market.  PERIOD.  FIA needs to provide detail ASAP on time to respond and specifically what they need to respond to.  The NR today was BS.  Inbox me.  i'll go the distance on this one.  I have asked these questions of Rob today and all i got was, "per the NR, we cannot provide timelines for FDA review/approval"  my response to Rob, was...."I get that Rob, but can you provide timelines on when you can respond to their questions and whether there is the need for another clinical trial"  Another clinical trial, if required, is material news and should be disclosed ASAP.  Rob failed to disclose this really.  Detail required.  More detail, otherwise, i'm ok to put him into big trouble myself.  Another Clinical trial is very material and should be disclosed to the market and all investors.  The NR today was BS.  With you.
<< Previous
Bullboard Posts
Next >>